Introduction
============

Chronic liver disease is the progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis (normally lasts 6 months). The etiologic agents of CLD include hepatotropic viruses (HBV and HCV), fatty liver, alcohol, autoimmune hepatitis, etc. The mortality of CLD patients remains high not only due to irreversible cirrhosis, but also multiple complications such as HCC and mental disease, especially depression.

Depression, also named MDD, MDE, or clinical depression, is a mental disorder characterized by a pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities. CLD has been long recognized and associated with depression ([@B43]; [@B88]). Clinical studies have shown that some patients with CLD have more severe depressive tendencies ([@B79]) than healthy ones. However, the underlying mechanisms of this association remain largely unknown, since previous studies used different diagnostic criteria to evaluate depression in chronic diseases. For example, [@B51] used standard psychiatric interview (Schedules of Clinical Assessment in Neuropsychiatry) to diagnose MDD in patients with diabetes and their first foot ulcer. In a cross-sectional study, [@B91] used the Hamilton depression rating scale (HDRS) in patients with CLD and found that depression was present in 62.9% of them. In addition, a number of studies on CLD have instead used self-report questionnaires ([@B7]; [@B29]; [@B25]).

Here, we summarize studies that used both conventional diagnostic criteria and questionnaires to identify depression in CLD \[especially in viral hepatitis, ALD, and NAFLD\], to point out the potential link between two diseases, which may provide more information to understand both diseases.

The Link Between Depression and Cld
===================================

Chronic Hepatitis B
-------------------

Chronic HBV infection is defined as the persistence of HBsAg and serum HBV--DNA levels detectable for at least 6 months. Globally, CH-B affects approximately 400 million people worldwide and contributes to more than one million deaths annually of liver disease ([@B57]). CH-B has become one of the major causes of chronic hepatitis, cirrhosis, and HCC worldwide. For patients with active viral replication, cirrhosis will be observed in 15--20% of patients within 5 years. Among patients with cirrhosis, the disease may progress, and the incidence of HCC is significantly elevated. 70--90% of patients with HCC have cirrhosis ([@B52]). It has been found that hepatitis B has a markedly negative impact on HRQOL, both in terms of physical function and mental health.

In 1984, Lok and his colleagues firstly studied the psychosocial effect of chronic HBV infection in 40 British carriers by using their own questionnaire. Thirty-six of these patients (90%) considered themselves that their physical and psychological health including sexual, work, social, and family attitudes, were negatively affected. Thirty-four of them experienced depression, 22 felt isolated especially initially, and 15 had feelings of guilt. In addition, 3 had sought, and 4 considered seeking psychiatric help ([@B63]). Although the sample size was small, this study indicates a potential relationship between CLD and depression. Consisting with this finding, a couple of years later, [@B56] evaluated 50 Korean immigrants who had CH-B or were healthy carriers for the HBV in terms of the relationships between their depression scores, psychosocial stressors, social support, and biological markers of dysfunction. All patients completed the BDI-sf ([@B47]), a self-report BDI screening test for depression that is scored as an index of severity of depressed mood. The average total BDI-sf score of them was 5.4 (BDI-sf scores \>5 means mild to severe depression). Twenty-three patients (46%) endorsed depressive symptomatology. Interestingly, higher depression scores were significantly associated with transaminase elevations both before and after BDI-sf administration, which discloses a more concrete relationship between depression and CLD than Lok's study, regardless their similar sample size and absence of controls. This limitation was much improved by a larger study from [@B117] in which the prevalence of depression was compared among patients with CH-B, CH-C, and NAFLD based on patient self-report and confirmed by examining history of prescription medication. In this study, a total number of 190 CH-B were enrolled, and only 7 (3.7%) had a diagnosis of depression ([@B117]). The low morbidity of depression in this study may be attributed to the missing self-report by the patients who had mild or moderate depression.

Actually, not only CH-B patients, but also HBsAg carriers need psychological therapies (**Table [1](#T1){ref-type="table"}**). [@B6] studied the psychiatric morbidity in a homogeneous group of asymptomatic HBV carriers by using the BDI, DSM IV Axis I (psychiatric disorders) and Axis V (global functioning assessment). They found that HBV carriers were more likely to have psychiatric disorders than healthy subjects (30.2% vs. 11.6%). Furthermore, carriers had significantly higher depression scores and lower GAF scores than comparison subjects. The high rates of psychiatric disorder in HBV carriers might be related to the frightening and potentially stigmatizing nature of hepatitis B ([@B6]). However, a Turkish study examining the effect of HBV infection on the psychological state of children showed no significant difference between asymptomatic carrier patients and control children with respect to depression scores. The different result may be explained by: (i) the absence of symptoms and insufficient information about children's status; (ii) the society protecting children from stigmatization ([@B5]). These possible explanations suggest that children are a special group and are not appropriate to compare with adults. Nevertheless, another study showed that the prevalence of depression increased significantly among CH-B patients in Iran (29.3%) after excluding inactive HBsAg carriers (10.0%), whereas it was similar between inactive HBsAg carriers and healthy participants (10.0% vs. 11.3%) ([@B76]). In contrast, [@B3] reported that 20% of CH-B patients were suffering from severe depression (score ≥ 17), and this number fell to 13.3 and 3.3% in HBsAg carriers and healthy controls, respectively. In addition, HRQOL scores in asymptomatic carriers were similar to those of non-cirrhotic CH-B patients, but worse than those of healthy controls ([@B3]).

###### 

The prevalence of depression in patients with CH-B.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients                              Methods                                                     Results                                                                                                                                                                                                    Reference
  ------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  40 British HBV carriers               Questionnaire                                               34 patients experienced depression\                                                                                                                                                                        [@B63]
                                                                                                    22 felt isolated\                                                                                                                                                                                          
                                                                                                    15 felt guilty\                                                                                                                                                                                            
                                                                                                    3 had sought and 4 considered seeking psychiatric help                                                                                                                                                     

  50 Korean CH-B Healthy HBV carriers   Clinical interview BDI-sf                                   23 patients (46%) endorsed depressive symptomatology                                                                                                                                                       [@B56]

  20 CH-B children patients\            CDI                                                         No difference between asymptomatic carrier and control group children with respect to depression scores                                                                                                    [@B5]
  20 asymptomatic carriers\                                                                                                                                                                                                                                                                                    
  43 healthy control                                                                                                                                                                                                                                                                                           

  43 asymptomatic carriers\             BDI-sf Structured Clinical Interview for DSM-IV GAF Scale   HBV carriers were more likely to have psychiatric disorders than comparison subjects (30.2% vs. 11.6%) Carriers had significantly higher depression scores and lower GAF scores than comparison subjects   [@B6]
  43 healthy controls                                                                                                                                                                                                                                                                                          

  30 CH-B patients\                     BDI-sf                                                      20% of CH-B patients were suffering from severe depression, 13.3% in HBsAg carriers, and 3.3% in healthy controls                                                                                          [@B3]
  30 inactive HBsAg carriers\                                                                                                                                                                                                                                                                                  
  30 healthy controls                                                                                                                                                                                                                                                                                          

  190 CH-B patients                     Self-report Examine history of prescription medication      3.7% CH-B patients had a diagnosis of depression                                                                                                                                                           [@B117]

  81 Iran CH-B patients\                HAMD-17                                                     Inactive HBsAg carriers and CH-B patients-excluding inactive HBsAg carriers-differed significantly in their prevalence of depression (10.0% vs. 29.3%)                                                     [@B76]
  80 healthy controls                                                                                                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BDI-sf, Beck Depression Inventory Short Form; CDI, Children's Depression Inventory; DSM, Diagnostic and Statistical Manual of Mental Disorders; GAF, Global Assessment of Functioning; 17-item Hamilton Depression Rating Scale (HAMD-17); HRQOL, health-related quality of life.

Chronic Hepatitis C
-------------------

Chronic hepatitis C is a worldwide health problem that affects approximately 170 million people globally (3%) ([@B58]; [@B77]). CH-C is now the most common cause of end-stage liver failure and the leading indication for liver transplant in the developed countries. Emerging evidence suggests that psychiatric problems, particularly depression, frequently occur in chronic infection with HCV and during antiviral treatment. As in other chronic medical illnesses, the presence of depression symptoms in CH-C is critical because they exhibit an adverse effect on the course of illness, with amplification of physical symptoms, functional impairment, and decreased compliance of treatment and quality of life ([@B29]).

High proportion of patients with CH-C had been diagnosed as having depression ([@B100]) (**Table [2](#T2){ref-type="table"}**). For example, [@B29] evaluated 50 CH-C patients using structured psychiatric interviews and standardized rating instruments, and found that 14 (28%) of patients had current depressive disorders, and their disability and fatigue were more closely related to depression severity than to hepatic disease severity. In another large study of 22341 HCV-infected veterans and 43267 healthy controls, [@B30] reported that patients were more likely to have depressive disorders than controls (49.5% vs. 39.1%). A recent study assessing the association between different types of CLD with depression in a population-based cohort showed that depression was strongly associated with CH-C ([@B59]). Furthermore, [@B41] studied 90 CH-C participants and demonstrated a 28% 1-month prevalence of depression, and 72% of whom were previously unidentified. [@B17] provided the evidence that CH-C was associated with MDD, independent of IFN-α treatment (32.6%).

###### 

The prevalence of depression in patients with CH-C.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients                                      Methods                                                     Results                                                                                                                                                                                                                                 Reference
  --------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  50 CH-C patients                              Structured psychiatric interview DSM IV BDI-sf21            14 (28%) of patients had current depressive disorders                                                                                                                                                                                   [@B29]

  22341 CH-C veteran patients\                  ICD-9 CM                                                    CH-C patients were more likely to have depressive disorders than healthy controls (49.5% vs. 39.1%)                                                                                                                                     [@B30]
  43267 controls                                                                                                                                                                                                                                                                                                                                    

  90 CH-C patients                              Structured Clinical Interview for DSM-IV Axis I Disorders   There was a 28% 1-month prevalence of depressive disorders, 72% of whom were previously undiagnosed.                                                                                                                                    [@B41]

  135 CH-C patients,\                           DSM-IV                                                      A significantly higher number of lifetime diagnoses of MDD among patients with CHC compared to controls (32.6% vs 12.8%), independent of IFN-α treatment.                                                                               [@B17]
  540 healthy control                                                                                                                                                                                                                                                                                                                               

  162 CH-C at baseline and treatment with IFN   20-item SDS                                                 Compared with baseline, mean SDS index scores were significantly increased by week 4 and remained elevated throughout the study. 39% of patients experienced moderate to severe depressive symptoms at some point during the therapy.   [@B101]

  325 CH-C patients                             MDI/DSM-IV criteria                                         19 patients (6%) had major depression at baseline and an additional 114 (37%) developed depression while on HCV combination therapy. Only 36 (32%) of the 114 patients developed major depression.                                      [@B60]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DSM, Diagnostic and Statistical Manual of Mental Disorders; BDI-sf, Beck Depression Inventory Short Form; ICD-9-CM, Clinical Modification of the International Classification of Diseases; SDS, Zung Self-Rating Depression Scale; MDI, Major Depression Inventory.

Alcoholic Liver Disease
-----------------------

Chronic excessive alcohol use is a common global health care concern and is associated with significant high morbidity and mortality. Approximately 20 to 30% of primary LTs are performed for patients with ALD ([@B32]; [@B1]; [@B109]). Alcohol use disorders are the second common indication for LTs in the US and Europe ([@B13]; [@B96]; [@B106]). The term "ALD" comprises a spectrum of pathologic characteristics including isolated steatosis, alcoholic steatohepatitis and established cirrhosis. Within this spectrum, varying degrees of inflammation, ballooning degeneration and hepatocyte necrosis, cholestasis, and fibrosis may be encountered ([@B99]).

Some researchers proposed that alcohol use may lead to depression symptoms as well as an increased risk of parasuicide and suicide ([@B38]; [@B16]). In contrast, others have found that depression may escalate alcohol use ([@B38]; [@B24]). Interestingly, a recent study showed that depression increased the risk of alcohol dependence only in men ([@B12]). These findings suggest that ALD may be associated with mental morbidity as well. Unsurprisingly, further studies reported that ALD was associated with depressive symptoms, particularly in the elderly ([@B16]; [@B105]; [@B86]). Given the aging of the US population, it is increasingly significant to evaluate the relationship between ALD and depression. In a cohort of patients with ALD including both cirrhotic and noncirrhotic, [@B33] showed that 40% of patients had psychiatric disorders, although there was no direct correlation between the degree of ALD and the likelihood of depression. In LT recipients with ALD, the psychologic stress from end-stage liver disease ([@B107]; [@B27]), surgical evaluation, and candidacy for LT ([@B26]), and subsequent surgery are risk factors in the development of depression ([@B22]; [@B27]). Regarding the association between ALD and depression, further research should investigate the bidirectional relationship between them.

Non-alcoholic Fatty Liver Disease
---------------------------------

Non-alcoholic fatty liver disease is the hepatic independent manifestation of the metabolic syndrome. The spectrum of NAFLD ranges from simple steatosis through NASH and fibrosis to 'cryptogenic' cirrhosis, HCC and other complications (liver failure and gastroesophageal varices) ([@B21]; [@B126]; [@B49]). NAFLD is strongly associated with obesity and insulin resistance-related metabolic features such as type 2 diabetes mellitus, hyperlipidemia, and systemic hypertension ([@B116]; [@B7]; [@B21]; [@B18]). With an aging and increasingly obese and diabetic population ([@B121]), the prevalence of NAFLD is significantly rising, leaving a public health concern among industrialized nations. Current estimates suggest that the prevalence in the general population is around one-third ([@B10]; [@B19]), rising in high-risk populations to as high as 70% ([@B4]; [@B112]). As a primary cause, NAFLD has become the third most common cause of LTs in the US (8.5%) ([@B18]).

There is growing evidence of links between NAFLD and depression. Several population-based studies have identified high prevalence of depression in patients with NAFLD. For instance, a study using a large population of CLD indicated that the prevalence of depression was significantly higher in patients with NAFLD compared with that in patients with CH-B (27.2% vs. 3.7%). They also found independent predictors of depression in this cohort were the presence of hypertension, smoking, history of lung disease, being female, and non-African--American. However, its clinical features were not explicitly stated ([@B117]). Another small matched case-control study by [@B31] showed that the prevalence of lifetime MDD was higher in the NASH population than that in control subjects matched for age, gender, BMI, and waist-hip ratio. Importantly, they found that the diagnosis of MDD tended to be associated with steatosis grade, after adjusting for other clinical confounders. In accordance with this, [@B125] also provided evidence that psychiatric disorders were associated with histological severity of liver diseases. They assessed a cohort of 567 North American patients with biopsy-proven NAFLD and demonstrated that subclinical and clinical depression were noted in 53 and 14% of NAFLD patients, respectively, Interestingly, depression was associated with more severe hepatocyte ballooning and patients with subclinical depression had a higher likelihood of having more severe portal fibrosis after adjusting for confounders ([@B125]). These results are consistent with another recent study by [@B113], in which NAFLD patients comorbid with MDD were characterized by more severe histological steatosis and higher NAFLD activity score. Moreover, serum aminotransferase, GGT, ferritin, and hs-CRP were dramatically higher in the NAFLD patients with MDD than those without MDD.

The Effect of Antiviral Medications on Liver and Depression
===========================================================

Depression is a condition not only associated with HCV infection, but also with pegylated IFN-α treatment in patients with CH-C. IFN-α-associated depression develops in a total of 30--70% of HCV-infected patients during treatment, in which mild to moderate depression accounts for 45--60%, moderate to severe depression, 15--40%, and major depression, 15--45% ([@B93],[@B95]; [@B101], [@B103], [@B102], [@B100]). The prevalence of IFN-α-associated depression is related to dosage and duration of treatment, and a previous history of psychiatric disorders ([@B102]; [@B60]). The prevalence depends on different assessment methods such as diagnostic interview, self-reports, clinical evaluation and observer-rated scales, and the severity of depression and the time of evaluation ([@B100]). Nevertheless, the type of IFN (pegylated or standard IFN), and combination therapy (IFN and RBV) have no significant impact on the prevalence of IFN-α-associated depression. A recent study by [@B60] showed that 10% of CH-C patients treated with pegylated IFN and RBV had to prematurely withdraw from treatment, because 65% of them (most did not undergo antidepressant therapy) had developed major depression, which might adversely affect the outcome from HCV treatment. A number of earlier studies reported that anti-depressive treatment might optimize the outcome of HCV antiviral therapy, particularly by reducing the risk of early treatment discontinuation ([@B55]; [@B73]; [@B93]). The recognition and treatment of pre-existing mental illness before HCV therapy yields improved tolerability and treatment response ([@B102]). Therefore, predicting psychiatric side effects of antivirus drugs is crucial for clinical research.

Risk Factors of Depression in Patients with Ch-C
================================================

Given that some patients are more likely to present depression during treatment with IFN-α, researchers have increasingly focused on identifying various social, clinical and biological factors that may lead to depression symptoms (**Table [3](#T3){ref-type="table"}**). The possibly substantial cultural differences, which exist between the societies in which the various quoted studies were conducted, might affect the risk of depression. Furthermore, stigmatization and the fact that CH-C patients have to fight with a chronic infectious disorder for a long time increase the occurrence of depression ([@B41]; [@B104]). A previous history of depression was also demonstrated to be a risk factor for the development of depression during antiviral therapy ([@B44]; [@B40]; [@B93]), while that was not observed in Leutscher's study ([@B60]). Other clinical risk factors such as fatigue and sleep disturbance strikingly heralded the emergence of depression ([@B40]; [@B60]). In addition, [@B48] found that age was another apparent risk factor, although divergent observations in this regard have been reported previously by [@B44]. They showed that there was no difference in age of CH-C patients between those who became IFN-induced MDD and those who did not. Similarly, some studies have yielded conflicting data with respect to female as a risk factor for the development of IFN-associated depression. Using multivariate regression analysis, [@B60] identified female as a significant independent predictor for subsequent development of major depression. This finding is similar to previous study showing the greater likelihood of female patients to develop depression during IFN-α-2B and RBV treatment of CH-C ([@B35]). However, [@B9] found no significant gender-related differences in the effects of IFN-α on the development of depression.

###### 

Potential risk factors of depression in patients with CH-C.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Social factors                                         Sociodemographic factors   Clinical factors                    Genetic factors (Polymorphisms)
  ------------------------------------------------------ -------------------------- ----------------------------------- ---------------------------------------------------------------------------
  Cultural differences Stigmatization Long time stress   Age\                       A previous history of depression\   5-HTTLPR (the s allele of the short/long polymorphism) 5-HTR1A (C-1019G)\
                                                         Female\                    Fatigue\                            IDO (rs9657182)\
                                                         Ethnicity                  Sleep disturbance                   IFNAR1\
                                                                                                                        Immune genes (IL-6, TNF-α)\
                                                                                                                        Others (PLA2, COX2, epsilon4)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-HTTLPR, the serotonin transporter gene-linked polymorphic region; 5-HTR1A, the serotonin 1A receptor; IDO, indoleamine-2,3-dioxygenase; PLA2, Phospholipase A2; COX2, cyclooxygenase 2.

Evidence for Genomic Influence in Modulating Depression
=======================================================

Polymorphisms in specific genes encoding several key players of the serotonergic system have been shown to confer an increased risk for depression in HCV patients during IFN therapy ([@B14]; [@B114]). Firstly, some studies have found the classical genetic risk factor for depression, the s allele of the short/long polymorphism within the 5-HTTLPR ([@B11]; [@B66]). Intriguingly, [@B90] investigated the functional role of these alleles (e.g., L~G~L~G~, L~G~S, and SS carriers were designated S'S' and found low expression levels) and demonstrated that in Hispanic HCV patients with IFN-α treatment, S' allele homozygotes showed markedly higher depression symptom scores. In contrast, among non-Hispanic Caucasians, L' allele homozygotes showed more depression symptoms than S' allele carriers did ([@B90]). These findings suggest that ethnicity might be associated with this classical genetic risk factor during IFN therapy. Secondly, the 5-HTR1A is one of the most abundant receptors in the hippocampus and has been previously reported in some affective disorders ([@B80]; [@B46]; [@B81]; [@B64]). [@B54] found that homozygosity for the G allele of the 5-HTR1A (C1019G) polymorphism in the promoter region of the 5-HT1A receptor gene conferred a higher risk for the development of IFN-induced depression compared to carriers with at least one C allele. In accordance with previous study, [@B23] demonstrated that this C-1019G polymorphism within the transcriptional control region of the 5-HTR1A gene independently predicted the incidence of IFN-induced depression in patients with CH-C. Thirdly, relevant to the metabolism of serotonin, much more attention has been paid on IDO, which breaks down TRP, the primary amino acid precursor for serotonin. Although the IDO enzyme seems to be involved in the pathophysiology of IFN-induced depression, [@B37] suggested that there was no influence of the variants in the IDO gene and the diagnosis of IFN-related depression in the Brazilian population. Interestingly, [@B108] found that in 800 Caucasians with CH-C, a polymorphism (rs9657182) in the promoter region of the gene encoding IDO was markedly associated with moderate or severe IFN-α-induced depression symptoms, whereas it did not predict depression in African Americans, who exhibited a significantly lower frequency of the risk allele at this locus ([@B108]). These observations confirm that ethnicity can modulate the risk for depression in CH-C during IFN therapy again. In addition to the serotonergic system, polymorphisms in the promoter region of the IFN-α/β receptor 1 (IFNAR1) can increase the risk of developing depression in HCV patients who are receiving antiviral treatments ([@B97]). Besides, a growing number of studies have also reported an association between polymorphisms in immune genes and the incidence of depression ([@B39]; [@B11]; [@B67]; [@B110]).

Shared Pathological Pathways
============================

Although the reasons for the high prevalence of depression in patients with CH-C are not very clear, emerging evidence has supported the hypothesis that HCV directly or indirectly induces biological changes in the CNS, which may result in psychiatric symptoms. In a previous study using proton magnetic-resonance spectroscopy, [@B36] demonstrated the elevations in basal ganglia and white matter choline/creatine ratios in patients with CH-C. Furthermore, the observation from [@B118] indicated the decreased alteration of serotonin and dopamine transporter binding in CH-C patients with chronic fatigue and cognitive impairment, which might be associated with depression. Of note, [@B42] provided further *in vivo* evidence for a neurotropic role for HCV. Using PET with a ligand for microglial/brain macrophage activation, ^11^C-(R)-PK11195 (PK11195) and cerebral proton magnetic resonance spectroscopy, they demonstrated that microglial activation was positively correlated with HCV viraemia and altered cerebral metabolism in the brains of patients with CH-C ([@B42]). Therefore, HCV may have a specific biological role in the development of depression.

Activated innate immunity and an acute-phase inflammatory response are commonly implicated in pathogenesis of CLD. Hepatic inflammation promotes the development of liver fibrosis (LF), cirrhosis and HCC, in which inflammasomes may play a key role. Inflammasomes are multi-protein complexes, which can sense endogenous and exogenous danger signals, ultimately activating the inflammatory process. Accumulating evidence supports an important role of the NOD-like receptors (NLRs) family pyrin domain containing 3 (NLRP3) inflammasome in the initiation and progression of CLD ([@B45]; [@B111]). A recent study showed that HCV RNA engagement of the NLRP3 inflammasome stimulated IL-1β secretion in KCs ([@B82]). In addition to viral hepatitis, [@B123] demonstrated the NLRP3 inflammasome was an essential contributor to LF during NASH development in mice. Furthermore, NLRP3 inflammasome activation led to hepatocyte pyroptosis, severe hepatic inflammation and HSC activation accompanied by collagen deposition in the liver ([@B122]). Interestingly, it has also been reported the relevance of the NLRP3 inflammasome in the pathogenesis of depression ([@B2]; [@B20]; [@B127]). Alcocer-Gómez observed increased gene expression of NLRP3 and caspase-1 in blood cells, and increased serum levels of IL-1β and IL-18 in MDD patients ([@B2]). Furthermore, the NLRP3 inflammasome was up-regulated in lipopolysaccharide-induced mice depressive-like behaviors ([@B128]). Importantly, some drugs conferred an antidepressant effect in a model of depression by inhibiting NLRP3 inflammasome activation ([@B68]; [@B62]; [@B124]; [@B61]). While the relationship of depression with CLD is complicated, shared biological mechanisms might underlie the association between depression and CLD in some individuals. The study focused on this underlying association will provide more information to understand both diseases. Overall, these findings indicate that the NLRP3 inflammasome is involved in the pathogenesis of depression and CLD, understanding its role in both diseases may build a linkage between them.

Molecular Mechanisms and Targets Underlying a Possible Connection
=================================================================

All studies above mostly focused on the prevalence of depression in patients with CLD, while few studies investigated the underlying biological mechanism, especially the potential effect of HBV on brain and peripheral blood. Importantly, there are many limitations in early studies: (i) the sample size is small and there is no control; (ii) missing self-report by patients who have mild or moderate depression; (iii) the distribution of HBV infection worldwide varies according to geographical zone ([@B87]). The impact of the carriage of HBV in highly epidemic (\>8%) areas such as South East Asia and Africa is greatly different from low epidemic areas (\<2%).

Recent advances have also been made to understand potential mechanisms leading to neuropsychiatric toxicity in CH-C patients treated with IFN-α. Numerous studies have indicated that significant alterations in serotonin, dopamine and norepinephrine neurotransmitter metabolism and activation of a pro-inflammatory cytokine network are involved in psychiatric disorders associated with IFN-α ([@B120]; [@B95]; [@B83]; [@B15]). Moreover, another mechanism underlying the psychiatric effects of IFN-α may involve alterations in neuroendocrine function. [@B94]. demonstrated that chronic exposure to IFN-α for 12 weeks in patients with CH-C was associated with a flattening of the diurnal ACTH and cortisol slopes, which might contribute to the altered diurnal HPA axis activity and behavior found in CH-C. However, in a previous study by [@B119], there was no relationship between daily average salivary cortisol concentrations or the cortisol awakening response and depression in HCV patients treated with IFN-α. In addition to neuroendocrine function, [@B34] investigated whether there might be any specific alteration in plasma biomarkers associated with MD in patients with CH-C. They followed up 50 HCV-infected patients (14 of them treated with IFN), and found that the occurrence of MD increased significantly in patients during IFN treatment. Importantly, lower baseline adiponectin levels and use of IFN were associated with MD development, which indicates that adiponectin may be a resilience biomarker for MD in patients with CH-C ([@B34]). Accumulating evidence also supported an important role for decreased BDNF activity in the development of depression during IFN-α treatment ([@B65]). In summary, these evidences showed that the alterations in monoamine metabolism, impaired neuroendocrine function, and plasma biomarkers are the major aetiological pathways for IFN-induced neuropsychiatric symptoms in patients with CH-C, which may be helpful to improve the management of HCV patients receiving antiviral treatment and illuminate the IFN-induced depression.

Underlying mechanism between NAFLD and depression remains unknown. However, the production of pro-inflammatory cytokines, and the increased cortisol and epinephrine levels in patients with depression may be one plausible explanation for the link between depression and NAFLD ([@B74]; [@B75]; [@B89]). Another potential explanation is the close correlation of NAFLD with obesity and diabetes mellitus, both of which have been strongly associated with depression symptoms ([@B69]; [@B84]; [@B92]; [@B115]; [@B78]). Nevertheless, this association cannot be fully explained by overweight status or poor adherence to therapy for diabetes alone, because anti-depressive treatment can improve insulin resistance and glycemic control ([@B69], [@B70]), which is independent of weight loss or adherence to diabetic treatment ([@B71], [@B72]; [@B85]).

Implications for the Clinical Management of Patients with Cld
=============================================================

Given the association of depression with severity of histological features of CLD, some investigators have focused on the influence of depression on the therapeutic effect of CLD. For example, [@B113] compared the NAFLD clinical response within different stages of MDD, and suggested that NAFLD patients comorbid with MDD had poor response to the 48 weeks standard care for NAFLD. In particular, NAFLD patients with unstable MDD (not in full/partial remission) had severe resistance to the treatment ([@B113]). In addition to the therapeutic effect, [@B98] performed a large sample meta-analysis to investigate the relationship between psychological distress (i.e., depression and anxiety) and liver disease (i.e., NAFLD and ALD) mortality using the 12-item GHQ. They found a significant increase in liver disease mortality with increase in GHQ score, which indicates that psychological distress is associated with mortality in CLD ([@B98]). Further research is needed to establish optimal management of depression in patients with NAFLD.

In addition to NAFLD, cirrhotic patients with depression experience worse health outcomes compared to matched patients without depression. In a previous study, [@B107] assessed for orthotopic LT in depressed patients with decompensated liver disease of different aetiologies and found that these patients had an increased mortality at 100 days post-assessment compared to non-depressed patients. One possible explanation for this result is biological theories that focus on the effect of depression upon the immune system (dysregulated secretion of immunomodulatory cytokines and impaired lymphocyte function), ultimately may increase the propensity of patients with liver disease to decompensation ([@B53]; [@B50]). Another explanation is psychological theories, which are based on the finding that depressed patients have high rates of noncompliance with medical regimens ([@B28]).

Besides, as stated above, development of depression is the commonest reason for treatment discontinuation in patients with CH-C ([@B60]). Taken together, CLD or orthotopic LT patients with depression experience worse clinical outcomes, including a reduced quality of life and increased mortality, than those without.

Conclusion
==========

This review summarizes the information on the prevalence and various risk factors of depression in patients with CLD, and shared biological pathways, as well as potentially molecular mechanisms for their association. Patients afflicted with CLD including CH-B, CH-C, NAFLD, and ALD manifest different degrees of depression symptoms, which can adversely affect clinical care and patient outcomes. In addition, patients with cirrhosis had signs of psychological distress and depression in relation to the severity of liver disease ([@B8]). The majority of the cases remain under-diagnosed, which indicates that it is necessary to conduct better-developed studies to investigate the effect of depression screening on CLD management in this population. In previous studies, inconsistent findings regarding the prevalence and depression treatment outcomes in patients with CLD seem partly attributable to some limitations, including inconsistencies in the definition and measurement of depression, non-probability sampling and the absence of group matching. Further research is needed to identify depression in large population-based prospective cohorts of patients with CLD, comparing them with healthy controls, with patients with other long-term disorders, across the life course.

Relative to many studies of the prevalence of depression in patients with CLD, mechanistic studies of depression have been sparse. Generally, the main reasons include the following aspects: (i) the disease itself: the long-term pain caused by disease and treatment, sexual dysfunction and feeling of guilt, worry about disease progression, and fear of infecting family and friends, etc. (ii) social and economic pressure, including fundamental conditions for studying and working, social discrimination and high cost of medical treatment. (iii) Drug therapy: IFN has been widely used to treat viral hepatitis, in the meantime, depression is much more prevalent in CLD patients with IFN treatment than that in patients without it. However, these are the common characteristics of all chronic diseases, which cannot explain why CLD patients have a high prevalence of depression. For example, the consensus suggests that worsened depression symptoms are noted in patients with CH-C, but whether these symptoms consistently correlate with poor liver function is still not fully elucidated, and knowledge of mechanisms for depression in patients with CH-C is limited. Additionally, it is still unknown whether depression could alter the liver tissue structurally and functionally. Further research needs to identify some biomarkers in both biological processes, to elucidate the potential biological correlations between depression and CLD. Large, well characterized cohorts are needed to test whether shared origins of depression and CLD exist at a genome-wide association significance level.
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:   chronic liver disease

CNS

:   central nervous system

DSM

:   Diagnostic and Statistical Manual of Mental Disorders

GAF

:   Global Assessment of Functioning

GGT

:   γ-glutamyl transpeptidase

GHQ

:   General Health Questionnaire

HBsAg

:   hepatitis B surface antigen

HBV

:   hepatitis B virus

HCC

:   hepatocellular carcinoma

HCV

:   hepatitis C virus

HPA

:   hypothalamic--pituitary--adrenal

HRQOL

:   health-related quality of life

HSC

:   hepatic stellate cell

hs-CRP

:   high-sensitivity C-reactive protein

IDO

:   indoleamine-2,3-dioxygenase

IFN

:   Interferon

IL

:   interleukin

KCs

:   kupffer cells

LT

:   liver transplantation

MDD

:   major depressive disorder

MDE

:   major depressive episode

NAFLD

:   non-alcoholic fatty liver disease

NASH

:   non-alcoholic steatohepatitis

NLRs

:   NOD-like receptors

NLRP3

:   NLRs family pyrin domain containing 3

NOD

:   nucleotide-binding oligomerization domain

PET

:   positron emission tomography

RBV

:   ribavirin

TRP

:   tryptophan
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